The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results
Developmental and epileptic encephalopathies (DEEs) are among the most challenging of all epilepsies to manage, given the exceedingly frequent and often severe seizure types, pharmacoresistance to conventional antiseizure medications, and numerous comorbidities. During the past decade, efforts have focused on development of new treatment options for DEEs, with several recently approved in the United States or Europe, including cannabidiol as an orphan drug in Dravet and Lennox-Gastaut syndromes and everolimus as a possible antiepileptogenic and precision drug for tuberous sclerosis complex, with its impact on the mammalian target of rapamycin pathway. Furthermore, fenfluramine, an old drug, was repurposed as a novel therapy in the treatment of Dravet syndrome. The evolution of new insights into pathophysiological processes of various DEEs provides possibilities to investigate novel and repurposed drugs and to place them into the context of their role in future management of these patients. The purpose of this review is to provide an overview of these new medical treatment options for the DEEs and to discuss the clinical implications of these results for improved treatment.
Keywords: Dravet syndrome; Lennox-Gastaut syndrome; antiseizure medications; cannabidiol; drug repurposing; everolimus; fenfluramine; orphan drugs; tuberous sclerosis.
© 2021 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
- Scheffer I, Bercovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-21.
- Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, et al. Revised terminology and concepts for organization of seizures and epilepsies: a report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51(4):676-85.
- Donner EJ, Camfield P, Brooks L, Buchhalter J, Camfield C, Loddenkemper T, et al. Understanding death in children with epilepsy. Pediatr Neurol. 2017;70:7-15.
- Berg AT, Nickels K, Wirrell EC, Geerts AT, Callenbach PM, Arts WF, et al. Mortality risks in new-onset childhood epilepsy. Pediatrics. 2013;132(1):124-31.
- Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortailty in Dravet syndrome. Epilepsy Res. 2016;128:43-7.